REG - BiVictriX Therapcts. - Grant of Options

Bivictrix TherapeuticsAnnouncement

13/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240813:nRSM1629Aa&default-theme=true

RNS Number : 1629A  BiVictriX Therapeutics PLC  13 August 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

Grant of Options

PDMR/Director Dealings

 

Alderley Park, 13 August 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug
discovery and development company applying an innovative, proprietary approach
to develop a new class of highly selective, next generation cancer
therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which
exhibit superior potency, whilst reducing treatment-related toxicities,
announces a grant of options over an aggregate of 2,717,776 ordinary shares of
1 pence each in the capital of the Company (the "Options") to certain
Directors/PDMRs of the Company.

 

The Options have an exercise price of 13 pence each, and will either vest over
three years, or be subject to the achievement of strategic corporate and
financial goals that the Board believes will create value for Shareholders.
The Options will expire ten years from the date of grant.

 

The Options have been awarded upon the recommendation of the Company's
Remuneration Committee and pursuant to the terms of the Company's Share Option
Plan, which was updated and adopted on 28 March 2024.

 

As part of this review and grant of Options, 1,032,667 of Tiffany Thorn's
previously awarded options, which were awarded at the time of the IPO in
August 2021, and were aligned to performance criteria, have subsequently been
cancelled due to the performance conditions assigned to them no longer being
regarded as appropriate for the business.

 

 The following Options have been granted to Directors/PDMRs of the Company:

 

 Director/PDMR  New Options granted  Options Cancelled  Total Options held
 Tiffany Thorn  2,197,776            1,032,667          6,862,109
 Susan Lowther  200,000              -                  200,000
 Oliver Schon   320,000              -                  1,136,333

 

Following this grant of Options, the total number of ordinary shares under
option is 11,113,443, representing 13.5 per cent. of the Company's total
issued share capital.

 

 

 ENDS

 

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman            Email:  info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)     Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Liberum Limited (Joint Broker)                Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 ICR Consilium
 Namrata Taak, Lucy Featherstone,                    Tel: +44 (0) 20 3709 5700

 Max Bennett, Emmalee Hoppe                          Email:  Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific
Bi-Cygni® fingerprints, which enable the Company to target a diverse array of
different cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug Conjugate
therapeutic design, to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and areas of high
unmet medical need.

 

Find out more about BiVictriX online at  www.bivictrix.com
(http://www.bivictrix.com/)

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         1)   Tiffany Thorn

                                                                    2)   Susan Lowther

                                                                    3)   Oliver Schon

 2.    Reason for the Notification
 a)    Position/status                                              1)    CEO

                                                                    2)    Non-Executive Director

                                                                    3)    VP, R&D

 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         BiVictriX Therapeutics plc
 b)    LEI                                                          213800ZI85IZNA6N3L53
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Ordinary Shares of 1 pence each

                                                                    GB00BNXH3K91
       Identification code
 b)    Nature of the transaction                                    Grant of Options
 c)    Price(s) and volume(s)                                       All Options have an exercise price of 13 pence each

Volume of Options
                                                                    1 )    2,197,776

                                                                    2)    200,000

                                                                    3)   320,000
 d)    Aggregated information:

       -   Aggregated volume

       -   Price                                                    Volume:  2,717,776 Options

                                                                    Exercise price of all Options: 13 pence each
 e)    Date of the transaction                                        13 August 2024
 f)    Place of the transaction                                     Outside a trading venue

d)

Aggregated information:

-   Aggregated volume

-   Price

 

 

Volume:  2,717,776 Options

 

 

Exercise price of all Options: 13 pence each

e)

Date of the transaction

  13 August 2024

f)

Place of the transaction

Outside a trading venue

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFZGMRGZMGDZZ